NCT06395844View on ClinicalTrials.gov

Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

May 1, 2025

Study Completion Date

December 31, 2026

Conditions
Ovarian Cancer
Interventions
DRUG

METR-NK cell(Metabolic Remodeling Nature Killer Cells)

The minimum amount of METR-NK cells infused each time should be no less than 7.5×10\^7 cells, Continuous infusion for 2 days constitutes one course, with 4 courses. The infusion is given every 2 weeks.

Trial Locations (1)

Unknown

RECRUITING

Anhui Cancer Hospital, Hefei

All Listed Sponsors
collaborator

Anhui Kecheng intelligent health technology Co., LTD

UNKNOWN

lead

Anhui Provincial Cancer Hospital

OTHER